Tadalafil Spray 30ml is a spray drug with Tadalafil as the core active ingredient, with a capacity of 30ml. Tadalafil belongs to the class of type 5 phosphodiesterase (PDE-5) inhibitors. By inhibiting PDE-5 enzyme activity, it prevents the degradation of cyclic guanosine monophosphate (cGMP), thereby relaxing smooth muscles, dilating blood vessels, and enhancing blood flow. This mechanism makes it a commonly used medication for treating male erectile dysfunction (ED), and is also approved as an adjuvant therapy for pulmonary arterial hypertension and benign prostatic hyperplasia (BPH). The spray type is designed to bypass the digestive tract metabolism process of traditional oral tablets through oral or mucosal absorption, reduce the damage of gastric acid and liver "first pass effect" on drugs, thus improving bioavailability and accelerating the onset time. A capacity of 30 milliliters usually contains a certain concentration of Tadalafil solution, and the specific dosage needs to be adjusted according to the product manual or doctor's advice.
Our products
 |
 |
 |
 |
 |
Additional information of chemical compound:
|
|
|
Tadalafil COA
Tadalafil Spray 30ml oral spray: open up a "new route" for absorption
Erectile dysfunction (ED) is a widespread and far-reaching issue in the field of men's health. The traditional treatment method is mainly oral Tadalafil tablets, which increase the level of cyclic guanosine monophosphate (cGMP) by inhibiting phosphodiesterase type 5 (PDE-5), thereby relaxing smooth muscles, dilating blood vessels, and improving erectile function. However, oral dosage forms require absorption through the gastrointestinal tract and first pass effects in the liver, resulting in delayed onset of action, limited bioavailability, and pain points such as swallowing difficulties and insufficient privacy. In this context, Tadalafil Spray 30ml oral spray has become a new choice in the field of ED treatment by virtue of its unique advantages of mucosal absorption, opening up a "new route" of drug absorption for patients.
The limitations of traditional oral dosage forms: the bottleneck of ED treatment
Pharmacokinetic defects: first pass effect and absorption delay
Oral Tadalafil requires dissolution in the stomach, absorption in the intestine, and ultimately enters the liver through the portal vein for metabolism. This process results in approximately 50% of drugs being inactivated due to first pass effects, with a bioavailability of only about 80%. In addition, drugs need to remain stable in the environment of gastric acid and digestive enzymes, and some patients may experience further reduction in absorption efficiency due to gastrointestinal diseases or drug interactions (such as antacids). Clinical data shows that traditional tablets have an onset time of 30 minutes to 1 hour, while high-fat diets may extend it to 2 hours, making it difficult to meet the "immediate" needs.
Medication Compliance Challenge: Contradiction between Privacy and Convenience
ED patients are highly sensitive to medication privacy, and traditional tablets need to be taken with drinking water, which can easily cause embarrassment in social situations such as gatherings and dates. In addition, patients with swallowing difficulties (such as the elderly or postoperative population) have a lower acceptance of tablets, and the complexity of daily regular medication (such as dose adjustment and time management) further reduces long-term compliance. A survey of 2000 ED patients showed that only 58% were able to adhere to taking tablets as needed, and less than 30% were regular users.
Side effect risk: Liver burden and drug interactions
Long term oral administration of tadalafil may increase the metabolic burden on the liver, especially in patients with concomitant chronic liver disease. Meanwhile, its interaction with nitrate ester drugs (such as nitroglycerin) may cause fatal hypotension, and when used in combination with CYP3A4 inhibitors (such as ketoconazole and rifampicin), dosage adjustment is required, increasing the complexity of medication management.
Technical breakthrough of oral spray: "through train" for mucosal absorption
Scientific basis of mucosal delivery system
The total area of oral mucosa is about 100cm ², composed of non keratinized epithelial cells with better permeability than the skin. Drugs enter the capillary network through intercellular lipids or cross cellular pathways, bypassing the first pass effect of the liver and directly entering the systemic circulation. Research shows that the bioavailability of oral spray is 30% -50% higher than that of oral tablet, and the onset time is shortened to 15-30 minutes.
Core advantages of Tadalafil Spray 30ml
Quick onset: Meeting "immediate needs"
The spray disperses the drug into micron sized particles (<10 μ m) through high-pressure atomization technology, and evenly covers the absorption parts such as sublingual and buccal mucosa. The rich capillary network of mucous membranes can rapidly uptake drugs. Clinical studies have shown that its onset time is more than 50% shorter than traditional tablets, and effective blood drug concentration can be achieved within 15 minutes, especially for patients planning temporary activities.
Privacy Protection: "Invisible Weapons" for Concealed Medication
The Tadalafil Spray 30ml bottle is designed to be compact and can be easily placed in a pocket or wallet, allowing for medication to be administered within 10 seconds without the need for water. Its lemon mint flavor formula masks the bitterness of the medicine and avoids awkward odors in social situations. A user experience survey on ED patients shows that 92% of users believe that sprays significantly improve medication privacy, and 85% prefer to carry them in public.
Dose Flexibility: A Precise Tool for Personalized Treatment
The spray device supports adjusting the dose according to the number of sprays (for example, each spray contains 2.5mg tadalafil) to meet the needs of different patients. For patients with renal insufficiency, the dosage can be reduced by decreasing the number of sprays; For regular medication users, spraying 2-3 times a day at a fixed time can maintain stable blood drug concentration and avoid the risk of missed doses of tablets.
Safety Enhancement: "Reducing Burden Effect" of Side Effects
Mucosal absorption reduces liver exposure and lowers the risk of drug-induced liver injury. At the same time, the spray does not pass through the digestive tract, avoiding the destruction of stomach acid on drugs, and reducing gastrointestinal side effects such as indigestion and abdominal pain. A phase III clinical trial showed that the incidence of headache and facial flushing in the spray group was 20% lower than that in the tablet group, and the incidence of muscle pain was 15% lower.
Clinical application scenarios: from "on-demand treatment" to "full cycle management"
On demand treatment: an "emergency plan" for responding to sudden needs
For patients who plan temporary activities, the spray can be used 15-30 minutes before the activity to quickly reach the effective blood concentration. Its portability is particularly suitable for business travel, long-distance dating and other scenarios, avoiding the trouble of planning medication time in advance for tablets.
Regular Treatment: A Long Term Partner for Chronic Disease Management
For ED patients with chronic diseases such as diabetes and hypertension, the spray supports regular use of low daily dose (2.5-5mg). Research has shown that long-term use can improve endothelial function and reduce the risk of cardiovascular events. In addition, the flexibility of dosage adjustment, such as adjusting the number of sprays based on renal function, provides a safer medication option for elderly patients.
Special populations: The "gospel" for people with swallowing difficulties
For postoperative patients, the elderly or patients with neurogenic ED, the spray does not need to swallow, avoiding the risk of throat sticking. A study on elderly ED patients showed that the success rate of spray (95%) was significantly higher than that of tablet (78%), and patient satisfaction increased by 30%.
Market prospects and challenges: the double-edged sword of innovative dosage forms
Market size and growth potential
The global oral spray market is expected to grow from 2.95 billion yuan in 2023 to 3.29 billion yuan in 2030, with a compound annual growth rate of 1.57%. Among them, the proportion of ED treatment sprays is small, but the growth rate is significant (CAGR will reach 12% in 2020-2025). The main driving factors include:
- Privacy requirements: Patients born in the 1980s and 1990s have higher demands for medication concealment;
- Technological innovation: Nano atomization technology improves drug absorption efficiency;
- Policy support: FDA, EMA and other institutions encourage the development of non injectable formulations
Future prospects: from "single treatment" to "ecological construction"
Technical iteration: the "next station" of intelligent spray
In the future, the spray may integrate sensor technology to monitor the blood concentration in real time and automatically adjust the dose. For example, by connecting to a mobile app via Bluetooth, the best medication plan can be recommended based on the patient's activity time and diet, achieving personalized and precise treatment.
Combination therapy: from "individual combat" to "synergistic efficiency"
The spray can be used together with testosterone gel, PDE-5 inhibitor topical patch, etc. to form a multimodal treatment scheme of "oral+local". For example, for testosterone deficient ED patients, sprays can rapidly improve erectile function, and testosterone gel can maintain hormone levels for a long time to achieve "treatment of both symptoms and root causes".
Global Market: From "Regional Leadership" to "Global Layout"
At present, North America and Europe account for 80% of the global ED spray market, but the Asia Pacific region has the fastest growth rate (CAGR will reach 15% in 2020-2025). Enterprises can reduce costs and expand into emerging markets through localized production (such as establishing GMP factories in China) and collaborative research and development (jointly developing generic drugs with Indian pharmaceutical companies).
FAQ
1. What are the key differences between the spray formulation and the tablet form?
It takes effect more quickly (usually within 15-30 minutes), avoids the first-pass effect, allows for more flexible dosage adjustment, and is suitable for those with swallowing difficulties. However, local mucosal absorption may be affected by the oral environment (such as pH and secretions).
2. How many times can the 30ml spray be used?
The exact number of sprays depends on the spray specification (commonly 2.5mg per spray or 5mg per spray). For example, if the concentration is 10mg/ml (total content 300mg), and each spray is 0.1ml (containing 1mg), then approximately 300 sprays can be made. Please refer to the product manual for details.
3. What should be particularly noted when using the spray?
Spray directly onto the oral mucosa (such as the underside of the tongue or the inner cheek), avoiding swallowing directly.
After spraying, temporarily refrain from eating or drinking to ensure full absorption.
Be aware of possible local irritation or abnormal taste sensation.
4. Can it be used for indications other than sexual functions (such as pulmonary hypertension)?
No. The dosage, absorption route and pharmacokinetics of the spray formulation are specifically designed for the treatment of erectile dysfunction. It has not been approved for use in other diseases. Prescription drugs for conditions such as pulmonary arterial hypertension that require specific formulations must be used strictly in accordance with medical advice.
Hot Tags: tadalafil spray 30ml, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale